Table 2.
Melanoma TMA Results of Categorically Scored Markers
| Marker | Serum LDH | p value | Adj. p value | |||
|---|---|---|---|---|---|---|
| Elevated n (%) | Not Elevated n (%) | |||||
| LDHA | ||||||
| 0 | 3 (9) | 13 (17) | ||||
| 1 | 23 (68) | 51 (68) | 0.3314 | 0.8837 | ||
| 2 | 8 (24) | 11 (15) | ||||
| Total | 34 | 75 | ||||
| LDHB | ||||||
| 0 | 0 (0) | 2 (3) | ||||
| 1 | 5 (20) | 9 (16) | 0.9078 | 1 | ||
| 2 | 20 (80) | 47 (81) | ||||
| Total | 25 | 58 | ||||
| PTEN | ||||||
| Absent | 11 (32) | 11 (15) | 0.0415 | 0.3320 | ||
| Total | 34 | 75 | ||||
| PD‐L1 clone 28‐8 | ||||||
| Positive (>5%) | 8 (24) | 10 (13) | 0.2643 | 1 | ||
| Total | 34 | 75 | ||||
| PD‐L1 clone 22C3 | ||||||
| Positive (>1%) | 11 (32) | 18 (24) | 0.3614 | 0.7228 | ||
| Total | 34 | 75 | ||||
The TMA analysis did not identify significant intratumoral alterations (adj. p value <0.05) in any of the listed markers between sLDH Elevated and sLDH Not Elevated distant metastases. Each marker is listed along with the scoring mechanism used for the analysis. Scores for samples are listed along with the total number of samples analyzed by each marker. Only markers scored categorically are included in the table.